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Abstract
Background: The methylenetetrahydrofolate reductase (MTHFR) gene variant C677T has been implicated as a
genetic risk factor in migraine susceptibility, particularly in Migraine with Aura. Migraine, with and without aura (MA
and MO) have many diagnostic characteristics in common. It is postulated that migraine symptomatic
characteristics might themselves be influenced by MTHFR. Here we analysed the clinical profile, migraine
symptoms, triggers and treatments of 267 migraineurs previously genotyped for the MTHFR C677T variant. The chi-
square test was used to analyse all potential relationships between genotype and migraine clinical variables.
Regression analyses were performed to assess the association of C677T with all migraine clinical variables after
adjusting for gender.
Findings: The homozygous TT genotype was significantly associated with MA (P < 0.0001) and unilateral head
pain (P = 0.002). While the CT genotype was significantly associated with physical activity discomfort (P < 0.001)
and stress as a migraine trigger (P = 0.002). Females with the TT genotype were significantly associated with
unilateral head pain (P < 0.001) and females with the CT genotype were significantly associated with nausea (P <
0.001), osmophobia (P = 0.002), and the use of natural remedy for migraine treatment (P = 0.003). Conversely, male
migraineurs with the TT genotype experienced higher incidences of bilateral head pain (63% vs 34%) and were
less likely to use a natural remedy as a migraine treatment compared to female migraineurs (5% vs 20%).
Conclusions: MTHFR genotype is associated with specific clinical variables of migraine including unilateral head
pain, physical activity discomfort and stress.
Background
Migraine is a complex, multifactorial disorder that
affects approximately 12% of the Caucasian population
[1]. At present, there are no biochemical tests to con-
firm the diagnosis of migraine; with diagnosis usually
achieved by matching the patient’s clinical manifesta-
tions to the classifications outlined by the International
Headache Society (IHS) [2]. The IHS defines two main
classes of migraine: migraine with aura (MA) and
migraine without aura (MO) [2]. Whilst the two sub-
types have significant symptomatic overlap, individuals
with MA experience a distinct phase of neurological dis-
turbances known as an “aura”, that usually precedes the
headache phase of an attack [3,4].
The human MTHFR gene mapped to chromosome
1p36.3 catalyses the nicotinamide adenine dinucleotide
phosphate (NADPH) dependent conversion of 5, 10-
methylenetetrahydrofolate (CH2-THF) to 5-methyltetra-
hydrofolate (CH3-THF), the principal circulatory form
of folate and a cofactor for methylation of homocysteine
to methionine [5,6]. An increase in circulatory homocys-
teine levels have been reported in patients with MA [7].
It is proposed that homocysteine acts as an excitatory
amino acid in migraine pathophysiology, either by caus-
ing vasodilation of cerebral blood vessels or temporary
thrombosis of cerebral blood vessels, reducing oxygen
into the brain [8,9]. Individuals carrying the C677T var-
iant in the MTHFR gene have been shown to have
decreased MTHFR enzyme activity, and the TT geno-
type is indirectly linked to mild hyperhomocystinemia
possibly resulting in vascular disease. The TT genotype
has been reported to be a modest, yet significant risk
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factor for stroke and hypertension [10,11]. The athero-
thrombotic effects of hyperhomocystinemia have been
postulated to increase the risk of stroke and the
decrease in MTHFR activity due to C677T mutation,
affecting DNA repair and cell division, may result in
hypertension [12].
The C677T allele (rs1801133), a common variant of
the MTHFR gene has a frequency of approximately 23-
41% in the Caucasian population [8,9,13]. Individuals
homozygous for this variant express approximately 30%
of the mean activity of MTHFR enzyme levels, as com-
pared with individuals without the substitution allele
[13,14]. The association of the C677T variant with MA
was first reported in a Japanese population and subse-
quently replicated in both Turkish and Dutch popula-
tion [8,15,16].
We investigated the MTHFR C677T variant in
migraine in an Australian Caucasian population and
have similarly shown significant over-representation of
the TT genotype in individuals with MA in comparison
to the control group [17]. This association was however
not seen in a Finnish study that investigated the contri-
bution of the C677T variant in MA and MO patients.
Interestingly, Schurks et al. [18] investigated the interre-
lationships of the MTHFR C677T variant, migraine and
cardiovascular disease, with data suggesting a protective
effect for the TT genotype against MA in their popula-
tion [18]. This inconsistency may be a result of allelic
heterogeneity, diagnostic variation or differences
between the populations examined [19].
As multiple genes have now been associated with
migraine susceptibility, it is plausible to assume that dif-
ferent genotypes and susceptibility genes may cause
varying disease manifestation [20,21]. Nyholt et al. [21],
through genome wide latent-class analysis (LCA) of
migraineurs, identified significant linkage on chromo-
some 5q21 and suggestive linkage on chromosomes 8,
10 and 13 in relation to migraine phenotypes. The study
investigated the broad contribution of chromosomal loci
to migraine clinical symptoms through linkage analysis,
but did not consider the effects of specific genes or
polymorphisms within genes [21]. A recent study by
Tietjen et al. [22], that investigated if angiotensin con-
verting enzyme (ACE) and MTHFR gene variants are
associated with von Willebrand factor (vWF) activity, an
endothelial dysfunction marker, and with a distinct
headache phenotype in premenopausal women with
migraine, observed elevated vWF activity to be asso-
ciated with the ACE DD genotype, which was highest
when combined with the MTHFR TT genotype [22].
The aim of the current study was to investigate
migraine phenotypes in relation to the MTHFR gene.
This study examined the genotype-phenotype correla-
tions between the C677T variant and the clinical
phenotypes of migraine to determine if the MTHFR
genotype was associated with migraine in general or
more specifically with particular migraine sub-types,
symptoms, severity, gender and/or response to
medication.
Methods
Details on the study population, questionnaire adminis-
tered, phenotypic variables investigated, and the meth-
ods used for DNA extraction from blood, polymerase
chain reaction, genotyping and statistical analyses are
provided in additional file 1.
Results
MTHFR genotypes associated with migraine clinical
variables
Table 1 shows results for MTHFR genotype analysis in
relation to migraine clinical variables. There were 165
MA and 102 MO participants in this study group. Six-
teen participants who experienced both MA and MO
were classified as having MA as they may share inher-
ited and acquired factors predisposing them to aura.
The MTHFR group consisted of 27% males and 73%
females. 94% of individuals with the MTHFR TT geno-
type, suffered from MA as compared to 61% and 55% of
individuals carrying the CC and CT genotypes respec-
tively. These results confirm our previous observations
[1,17].
Of the 50 variables tested and after Bonferroni correc-
tion for multiple testing, migraine diagnosis (P < 0.0001,
degree of freedom (df) = 2), unilateral head pain (P =
0.002, df = 2), physical activity discomforts (P < 0.001,
df = 2) and stress as a migraine trigger (P = 0.002, df =
2) were all factors that were significantly associated with
MTHFR genotype (Table 2). Further analyses demon-
strated the TT genotype to be significantly associated
with MA (P < 0.0001) and unilateral head pain (P =
0.002). Frequency data found 87% of migraineurs with
the TT genotype experienced unilateral head pain com-
pared to 62% in the CC group. The CT group showed
an intermediate percentage of migraineurs who experi-
enced unilateral head pain (77%). A smaller percentage
of migraineurs carrying the CC genotype experienced
discomfort associated with physical activity during or
just prior to migraine (69%), while the TT group had an
intermediate response (83%) and the CT (88%) group
had the highest response (P < 0.001). The CT genotype
group also had the highest percentage of participants
acknowledging stress as a migraine trigger (76%) (P =
0.002) (Table 2). These findings suggest that individuals
carrying one and/or more copies of the T allele are
more prone to unilateral head pain, are more likely to
experience discomfort associated with physical activity
during or prior to migraine and have stress as a
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migraine trigger compared to those carrying the CC
genotype.
To further analyse the contribution of the recessive
TT genotype with migraine clinical variables, the CC
and the CT groups were reclassified into one group, and
compared with the TT genotype group. The chi-square,
Kruskal-Wallis and Kolmogorov-Smirnov Z tests
between the two reclassified genotype groups and
migraine clinical data revealed statistical significance of
genotype with migraine diagnosis (P < 0.000, df = 1)
and visual disturbances (P= 0.001, df = 1). Frequency
data demonstrated the recessive TT genotype group had
a significantly higher percentage of individuals with MA;
while the CC/CT genotype group appeared to have an
equal distribution of the two different migraine
subtypes.
Gender differences and the MTHFR genotype
The inclusion of gender as an independent variable
revealed gender specific statistical significance for a
number of migraine clinical variables. In female migrai-
neurs the TT genotype was significantly associated with
unilateral head pain (OR = 0.35, CI-95 = 0.15-0.79, P <
0.001). Conversely, male migraineurs experienced higher
incidences of bilateral head pain, especially in those with
the TT genotype, compared to female migraineurs (67%
Table 1 Chi square analysis of MTHFR genotype for
individuals experiencing clinical variables versus all
migraineurs who do not
Clinical variables Pearson’s
chi-square
N P-value
Migraine Subtype Diagnosis 16.65 < 0.001
Visual disturbances 5.57 96 0.062
Numbness & Tingling 1.49 45 0.475
Speech problems 1.41 26 0.493
Nausea 0.15 165 0.927
Emesis 0.69 121 0.708
Diarrhoea 2.3 18 0.316
Phonophobia 2.16 153 0.34
Photophobia 0.85 177 0.654
osmophobia 3.78 42 0.151
Altered Vision 0.52 81 0.77
Dizziness/Double Vision 4.33 49 0.115
Speech problems 1.78 31 0.411
Numbness & Tingling 0.1 49 0.952
Weakness 2.7 54 0.259
Pulsating & throbbing head pain 1.23 158 0.542
Unilateral head pain 7.07 123 0.029
Bilateral head pain 2.76 66 0.251
Head movement discomfort 2.72 123 0.257
Eye Movement discomfort 3.59 97 0.166
Physical Activity discomfort 8.97 149 0.011
Migraine triggers
Menses 1.224 58 0.542
Weather Changes 0.98 36 0.613
Stress 7.3 123 0.026
Holiday & Relaxation 3.29 17 0.193
Red Wine 2.5 33 0.286
Other Alcohol 1.48 35 0.478
Chocolate 0.5 46 0.799
Oranges 0.21 23 0.902
Ripe Cheese 4.32 23 0.115
Migraine treatment
Yes/No 0.04 58 0.981
5-HT1 Drugs 0.03 30 0.985
5-HT1 Drug treatment effectiveness 1.97 21 0.373
Pain killers 5.02 137 0.081
Natural remedy 1.77 27 0.412
Medication for nausea 2.75 31 0.253
Treatment for other conditions/pains
Yes/No 0.67 17 0.716
Chronic neck pain 1.98 33 0.372
High blood pressure 0.08 16 0.916
Stroke 0.93 1 0.629
Heart Disease 1.5 7 0.473
Depression 1.68 23 0.431
Anxiety disorder 0.32 2 0.853
Panic disorder 0.21 6 0.899
Chronic fatigue 1.71 5 0.425
Irritable bowel 3.22 15 0.2
Table 2 Genotypic frequency distribution of MTHFR and
statistically significant clinical variables in relation to
MTHFR genotype
Clinical variables Subtype (Total) MTHFR Genotype %
CC CT TT
Migraine Diagnosis MO (102) 39 (39%) 61 (45%) 2 (6%)
P < 0.0001 MA (165) 61 (61%) 74 (55%) 30 (94%)
Unilateral head pain Y (123) 40 (62%) 63 (77%) 20 (87%)
P < 0.0001 N (47) 25 (38%) 19 (23%) 3 (13%)
Physical activity Y (149) 51 (69%) 78 (88%) 20 (83%)
P < 0.001 N (38) 23 (31%) 11 (12%) 4 (17%)
Stress Y (123) 42 (61%) 68 (76%) 13 (52%)
P = 0.002 N (60) 27 (39%) 21 (24%) 12 (48%)
Significant P values after correction for multiple testing (Bonferroni
correction).
MO = Migraine without aura, MA = Migraine with aura, Y = Yes and N = No.
Table 1 Chi square analysis of MTHFR genotype for indi-
viduals experiencing clinical variables versus all migrai-
neurs who do not (Continued)
Menstrual problems 1.19 14 0.551
Chronic back pain 0.95 1 0.623
Contraceptive Pill 0.177 67 0.915
Passive Smoking 0.1 81 0.952
*P values are values of c2 tests (2tailed) for the 2 × 3 tables (df = 2).
Liu et al. BMC Research Notes 2010, 3:213
http://www.biomedcentral.com/1756-0500/3/213
Page 3 of 6
vs 19%)(Table 3). In addition, female migraineurs with
the CT genotype were more likely to suffer from nausea
(OR = 3.41, CI-95 = 1.44-8.08, P < 0.001), osmophobia
(OR = 3.39, CI-95 = 1.01-10.48, P = 0.002) and use nat-
ural remedy as a migraine treatment (OR = 0.2, CI-95 =
0.05-0.92, P = 0.003) compared to male migraineurs
(Tables 4).
Discussion
Migraine is most likely produced as a result of the inter-
action between multiple genes with environmental fac-
tors and triggers. As a consequence, variability and
overlap is expected in the manifestations of the asso-
ciated genetic defect/s. In a study of the clinical mani-
festations associated with mutations in the calcium-
channel, voltage dependent, P/Q type, alpha A subunit
gene (CACNA1A) in 28 families with Familial Hemiple-
gic Migraine type 1, Ducros et al (2001) [3], revealed
significant genotype-phenotype correlations. In addition
to clinical variability being partly due to the different
CACNA1A mutations, the study also suggested that
variability in phenotypic expression among patients with
the same mutation could be influenced by other genetic
or environmental factors.
The study of vascular genes in migraine identified
a role for MTHFR gene. MTHFR synthesizes
5-methylenetetrhydrofolate, the major carbon donor
required for efficient remethylation of homocystein to
methionine [23]. The MTHFR C677T allele results in an
amino acid change and reduces MTHFR enzyme activity
leading to mild hyperhomocysteninemia [13]. Hyperho-
mocysteninemia have been suggested to produce
endothelial cell injury in animal and cell culture studies;
this homocysteine related dysfunction of the vascular
endothelium may potentially influence migraine suscept-
ibility, especially MA, through the activation of trigem-
inal fibres [24-26]. It is possible that the vascular
disturbance connected to hyperhomocysteinemia trigger
downstream neurological manifestations that are
observed in MA sufferers.
The current study investigated genotype-phenotype
correlations of the migraine susceptibility gene, MTHFR
with 50 migraine clinical variables. Even after correction
for multiple testing, analyses indicated the MTHFR gen-
otype to be significantly associated with migraine diag-
nosis, unilateral head pain, physical activity discomforts,
and stress as a migraine trigger. The homozygous
MTHFR TT genotype was linked with MA and unilat-
eral head pain and the heterozygous CT genotype was
linked to physical activity discomforts during or prior to
migraine and stress as a migraine trigger. While the TT
and CC genotypes showed the highest and the lowest
percentage of participants suffering from unilateral head
pain during or prior to a migraine respectively, the CT
genotype clearly demonstrated an intermediate response.
Frequency data of participants suffering from physical
activity discomfort during or prior to migraine showed
the CT and the CC genotypes to have the highest and
the lowest percentage of participants respectively and
the TT genotype showed an intermediate response.
Interestingly, the CT and the TT genotypes showed the
highest and the lowest number respectively, of migrai-
neurs reporting stress as a migraine trigger.
When the MTHFR genotype groups were examined
by comparing CC and CT genotypes to the homozygous
TT genotype, the resulting regression models did not
alter drastically. The TT genotype remained significantly
linked to MA and was also observed to be significantly
associated with visual disturbance. When gender differ-
ences were investigated in relation to genotype and phe-
notype it was found that bilateral head pain was
observed more commonly in male migraineurs. In con-
trast, in females, nausea, unilateral head pain, osmopho-
bia and the use of natural remedy as a migraine
treatment were significantly associated with one or
more copies of the T allele. The gender distribution in
this study is not equal with 27% of the participants
being males and 73% of the participants being females;
some caution has to be exercised when interpreting the
significant results. Gender differences in relation to
Table 3 Genotypic frequency distribution of MTHFR for
statistically significant clinical variables in relation with
gender
Clinical variables Gender MTHFR Genotype %
CC CT TT
Nausea M 10(100%) 15(60%) 5(71%)
F 55(85%) 64(94%) 16(89%)
Osmophobia M 1(13%) 3(14%) 0(0%)
F 15(26%) 21(35%) 2(13%)
Unilateral head pain M 4(50%) 15(65%) 3(50%)
F 36(63%) 48(81%) 17(100%)
Bilateral head pain M 5(62%) 13(62%) 4(67%)
F 26(46%) 15(26%) 3(19%)
Natural Remedy M 0(0%) 2(9%) 0(0%)
F 8(15%) 14(25%) 3(19%)
Table 4 Statistically significant clinical variables by
gender and MTHFR genotype
Clinical variables P-value OR OR (95% CI)
Nausea < 0.001 3.41 (1.44-8.08)
Osmophobia = 0.002 3.39 (1.01-10.48)
Unilateral head pain < 0.001 0.35 (0.15-0.79)
Bilateral head pain < 0.000 0.25 (0.11-0.55)
Natural remedy = 0.003 0.2 (0.05-0.92)
Significant P values after correction for multiple testing (Bonferroni
correction).
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genotype and phenotype have to be examined in a
bigger cohort to look at the effect of MTHFRC677T
genotype on migraine clinical symptoms diligently.
The TT genotype of the MTHFR C677T variant has
been shown in several studies including a recent meta-
analysis by Rubino et al [27] to confer a modest risk for
MA [27]. This study expanded on this association to
examine genotype-phenotype correlations between the
C677T variant and the clinical phenotypes of migraine.
The presence of the T allele was associated with the lar-
gest number of migraine symptoms and triggers, sug-
gesting that although the TT genotype appears to have
a recessive effect on MTHFR enzyme levels, perhaps
both heterozygous and homozygous states of the T allele
may contribute to the phenotypic expression of
migraine. As well as intrinsic enzyme levels, individuals
with the CT genotype may be more susceptible to the
environmental triggers associated with migraine attacks.
The effects of elevated levels of homocysteine on neu-
rons have been reported to include DNA damage,
altered DNA repair, disturbance in DNA methylation
and oxidative stress [26,28-30]. Animal studies have
reported cytotoxic effects of high levels of homocysteine
to included apoptosis in sensitive brain areas such as
the striatum and cerebellum involved in motor function
and altered neurobehavioural capacity in rat models
[31]. It is thus plausible that the resulting levels of
homocysteine conferred by the T allele may contribute
to selected phenotypic expressions described in
migraineurs.
The major limitation of the present study was the
number of available subjects in comparison to the num-
ber of outcome variables examined. As such, further
investigations utilising larger populations to clarify the
genotype-phenotype interactions of the migraine sus-
ceptibility gene MTHFR are warranted.
Conclusion
This study examined the contribution of the C677T
genotype of the migraine susceptibility gene MTHFR,
to migraine subtypes, triggers, severity, symptoms and
response to medication. Interestingly, the TT genotype
of the MTHFR gene, while being significantly corre-
lated to MA as expected, was also found to be asso-
ciated with the largest number of migraine symptoms
and triggers.
Additional material
Additional file 1: Detailed Methods. A detailed description of the
methods used in recruitment and selection of participants used for this
study, including genotyping and statistical analyses.
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